303-53-7 Categories: , ,
  • # LGM Pharma is a Cyclobenzaprine CAS# 303-53-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Cyclobenzaprine
  • CAS #: 303-53-7
  • Mode of Action:

    Like other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons.

  • Pharmacodynamics:

    Cyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease.

  • Metabolism:

    Extensively metabolized (gastrointestinal and hepatic).

  • Toxicity:

    Oral mouse and rat LD50 are 338 mg/kg and 425 mg/kg respectively. Signs of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.

  • IUPAC: dimethyl(3-{tricyclo[³, ⁸]pentadeca-1(15), 3, 5, 7, 9, 11, 13-heptaen-2-ylidene}propyl)amine
  • ATC: M03BX08
  • PubChem: 2895
  • DrugBank: DB00924 (APRD00213)
  • Formula: C20-H21-N
  • Molecular Mass: 275.3929
  • Synonyms: 10,11-Dehydroamitriptyline, 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene, 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian], 9715 R.P., Ciclobenzaprina, Ciclobenzaprina [INN-Spanish], Cyclobenzaprine, Cyclobenzaprinum, Cyclobenzaprinum [INN-Latin], EINECS 206-145-8, Fexmid, Lisseril, MK 130, N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, Proeptatriene, Proeptatriene [Italian], Proheptatrien, Proheptatriene, Ro 4-1577, UNII-69O5WQQ5TI
  • SMILES: CN(C)CCC=C1c2ccccc2C=Cc3c1cccc3
  • AHFS Code: 12:20.0
  • InChl: 1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service